Bal Pharma

{
  "main_header": {
    "sid": 555664,
    "name": "Bal Pharma",
    "stock_name": "Bal Pharma",
    "full_name": "Bal Pharma Ltd",
    "name_url": "stocks-analysis/bal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "87.58",
    "chg": -0.75,
    "chgp": "-0.85%",
    "dir": -1,
    "prev_price": "88.33",
    "mcapval": "142.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524824,
    "symbol": "BALPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE083D01012",
    "curr_date": "Jun 03, 03:30 PM",
    "curr_time": "22:44 PM",
    "last_traded_at": "Jun 03, 03:30 PM IST",
    "bse_nse_vol": "85.31 k",
    "exc_status": "Active",
    "traded_date": "Jun 03, 2026",
    "traded_date_str": "2026 06 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bal-pharma-555664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bal Pharma Ltd Downgraded to Strong Sell Amid Mixed Valuation and Weak Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-downgraded-to-strong-sell-amid-mixed-valuation-and-weak-financial-trends-4030112",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalPharmaLtd_mojoScore_4030112.png",
        "date": "2026-06-02 08:38:19",
        "description": "Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This shift reflects a combination of deteriorating technical indicators, flat financial performance, and a cautious valuation outlook despite some attractive metrics. The company’s shares have also declined sharply, falling 4.61% on the day following the announcement, underscoring investor concerns."
      },
      {
        "title": "Bal Pharma Ltd Valuation Shifts to Very Attractive Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bal-pharma-ltd-valuation-shifts-to-very-attractive-amid-market-volatility-4025226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalPharmaLtd_valuationdot_4025226.png",
        "date": "2026-06-01 08:03:11",
        "description": "Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a recent day decline of 6.82%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point compared to its peers and historical averages."
      },
      {
        "title": "Bal Pharma Gains 10.11%: Technical Upgrade and Q4 Profit Surge Drive Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bal-pharma-gains-1011-technical-upgrade-and-q4-profit-surge-drive-volatility-4023430",
        "imagepath": "",
        "date": "2026-05-30 17:03:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>25 May:</strong> Stock jumps 8.06% to Rs.88.57 on strong volume</p>\n                    <p><strong>26 May:</strong> MarketsMOJO upgrades rating to Sell amid technical improvements</p>\n                    <p><strong>27 May:</strong> Stock hits weekly high of Rs.96.86 following upgrade</p>\n                    <p><strong>29 May:</strong> Q4 FY26 results reveal profit surge but revenue decline; stock falls 6.82%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n                        <div class=\"stat-value\">Rs.81.96</div>\n                    </div>\n           ..."
      },
      {
        "title": "Are Bal Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bal-pharma-ltd-latest-results-good-or-bad-4021819",
        "imagepath": "",
        "date": "2026-05-29 19:41:17",
        "description": "Bal Pharma Ltd's latest financial results for Q4 FY26 present a mixed picture. The company reported a net profit of ₹3.59 crores, reflecting a significant sequential improvement of 101.69% compared to the previous quarter. However, this figure represents a decline of 33.89% year-on-year, indicating challenges in maintaining profitability over a longer period. \n\nRevenue for the quarter stood at ₹84.08 crores, which is a decrease of 4.12% from the previous quarter but shows a modest year-on-year growth of 2.69%. This suggests that while the company has experienced some volatility in its revenue streams, it has managed to achieve slight growth compared to the same quarter last year.\n\nOperating margins have expanded to 12.57%, marking the highest level in recent quarters and reflecting improved cost management strategies. This margin expansion is notable, particularly given the context of declining revenues, an..."
      },
      {
        "title": "Bal Pharma Q4 FY26: Profitability Surge Masks Revenue Decline Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/bal-pharma-q4-fy26-profitability-surge-masks-revenue-decline-concerns-4020576",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalPharma_quaterlyResult_4020576.png",
        "date": "2026-05-29 09:40:27",
        "description": "Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported a consolidated net profit of ₹3.59 crores for Q4 FY26, representing a dramatic sequential surge of 101.69% from ₹1.78 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 33.89% decline from ₹5.43 crores in Q4 FY25. The company's shares traded at ₹91.50 on May 29, 2026, down 5.53% from the previous close, reflecting investor caution despite the sequential improvement."
      },
      {
        "title": "Bal Pharma Ltd Upgraded to Sell on Technical Improvements Despite Fundamental Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-upgraded-to-sell-on-technical-improvements-despite-fundamental-challenges-4015925",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalPharmaLtd_mojoScore_4015925.png",
        "date": "2026-05-27 08:12:23",
        "description": "Bal Pharma Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and flat financial performance continue to weigh on its long-term outlook, but recent technical trends suggest a stabilising price action that has prompted a more favourable, albeit cautious, stance."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-4002686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalPharmaLtd_mojoScore_4002686.png",
        "date": "2026-05-21 10:10:58",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below are based on the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "When is the next results date for Bal Pharma Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-bal-pharma-ltd-3999679",
        "imagepath": "",
        "date": "2026-05-19 23:17:37",
        "description": "The next results date for Bal Pharma Ltd is scheduled for 27 May 2026...."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3983925",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BalPharmaLtd_mojoScore_3983925.png",
        "date": "2026-05-10 10:10:37",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      }
    ],
    "total": 144,
    "sid": "555664",
    "stock_news_url": "https://www.marketsmojo.com/news/bal-pharma-555664"
  },
  "announcements": [
    {
      "caption": "Non Applicability Of Statement Of Deviation & Variation",
      "datetime": "29-May-2026",
      "details": "Filing of Statement of deviation & variation is not applicable to the Company for the quarter ended 31.03.2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "29-May-2026",
      "details": "We are submitting the newspaper advertisements of the Audited financial results ( standalone & Consolidated ) for the quarter and financial year ended 31.03.2026 announced by the Company on 27.05.2026 and published in Financial express (English ) and Sanjayvani ( Kannada) on 29.05.2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
      "datetime": "27-May-2026",
      "details": "Board of Directors of the Company has met today and transacted following business 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend dividend of Rs1.20 per equity share of Rs.10 each i.e 12% 3.Appointed Cost Auditors and Internal auditors for the financial year 2026.27. 4. Approved grant of 500000 stock options to the employees of the company under Bal Pharma Ltd-Employee Stock Option Plan-2025 5.Approved preferential issue of 1000000 warrants to the promoters. 6. Take shareholders approval for preferential issue through postal ballot. 7.Approved appointment of Mr.Shreepada M.L (M # A66681) as Company Secretary and compliance officer of the company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bal Pharma Ltd has declared <strong>12%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bal Pharma Ltd Downgraded to Strong Sell Amid Mixed Valuation and Weak Financial Trends

2026-06-02 08:38:19

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This shift reflects a combination of deteriorating technical indicators, flat financial performance, and a cautious valuation outlook despite some attractive metrics. The company’s shares have also declined sharply, falling 4.61% on the day following the announcement, underscoring investor concerns.

Read full news article

Bal Pharma Ltd Valuation Shifts to Very Attractive Amid Market Volatility

2026-06-01 08:03:11

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a recent day decline of 6.82%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point compared to its peers and historical averages.

Read full news article

Bal Pharma Gains 10.11%: Technical Upgrade and Q4 Profit Surge Drive Volatility

2026-05-30 17:03:23

Key Events This Week

25 May: Stock jumps 8.06% to Rs.88.57 on strong volume

26 May: MarketsMOJO upgrades rating to Sell amid technical improvements

27 May: Stock hits weekly high of Rs.96.86 following upgrade

29 May: Q4 FY26 results reveal profit surge but revenue decline; stock falls 6.82%

Week Open

Rs.81.96

...

Read full news article

Are Bal Pharma Ltd latest results good or bad?

2026-05-29 19:41:17

Bal Pharma Ltd's latest financial results for Q4 FY26 present a mixed picture. The company reported a net profit of ₹3.59 crores, reflecting a significant sequential improvement of 101.69% compared to the previous quarter. However, this figure represents a decline of 33.89% year-on-year, indicating challenges in maintaining profitability over a longer period. Revenue for the quarter stood at ₹84.08 crores, which is a decrease of 4.12% from the previous quarter but shows a modest year-on-year growth of 2.69%. This suggests that while the company has experienced some volatility in its revenue streams, it has managed to achieve slight growth compared to the same quarter last year. Operating margins have expanded to 12.57%, marking the highest level in recent quarters and reflecting improved cost management strategies. This margin expansion is notable, particularly given the context of declining revenues, an...

Read full news article

Bal Pharma Q4 FY26: Profitability Surge Masks Revenue Decline Concerns

2026-05-29 09:40:27

Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported a consolidated net profit of ₹3.59 crores for Q4 FY26, representing a dramatic sequential surge of 101.69% from ₹1.78 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 33.89% decline from ₹5.43 crores in Q4 FY25. The company's shares traded at ₹91.50 on May 29, 2026, down 5.53% from the previous close, reflecting investor caution despite the sequential improvement.

Read full news article

Bal Pharma Ltd Upgraded to Sell on Technical Improvements Despite Fundamental Challenges

2026-05-27 08:12:23

Bal Pharma Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and flat financial performance continue to weigh on its long-term outlook, but recent technical trends suggest a stabilising price action that has prompted a more favourable, albeit cautious, stance.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-05-21 10:10:58

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below are based on the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

When is the next results date for Bal Pharma Ltd?

2026-05-19 23:17:37

The next results date for Bal Pharma Ltd is scheduled for 27 May 2026....

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-05-10 10:10:37

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

View All News